prednisolone has been researched along with Pneumococcal Infections in 12 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Pneumococcal Infections: Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.
Excerpt | Relevance | Reference |
---|---|---|
"To compare antibody responses to 23-valent pneumococcal vaccine (Pneumovax) in controls and patients with established rheumatoid arthritis (RA) treated with TNF blockers, methotrexate (MTX) or a combination of both." | 7.73 | Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. ( Geborek, P; Jönsson, G; Kapetanovic, MC; Saxne, T; Sjöholm, A; Truedsson, L, 2006) |
" About two months before this admission the patient was diagnosed as Henoch-Schönlein purpura nephritis who was treated with 40 mg/day of prednisolone(PSL)." | 3.74 | [Infective endocarditis successfully treated by early medical therapy in a patient with Henoch-Schönlein purpura nephritis under oral steroid therapy]. ( Iwasaki, S; Nagayama, Y; Yamaguchi, H; Yoshimura, A, 2007) |
"To compare antibody responses to 23-valent pneumococcal vaccine (Pneumovax) in controls and patients with established rheumatoid arthritis (RA) treated with TNF blockers, methotrexate (MTX) or a combination of both." | 3.73 | Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. ( Geborek, P; Jönsson, G; Kapetanovic, MC; Saxne, T; Sjöholm, A; Truedsson, L, 2006) |
"Bacterial keratitis results in corneal scarring and subsequent visual impairment." | 1.39 | Improvement in corneal scarring following bacterial keratitis. ( Acharya, NR; Greninger, DA; Keenan, JD; Lietman, TM; Mascarenhas, J; McClintic, SM; Srinivasan, M, 2013) |
"In rabbit models of untreated Pseudomonas keratitis and pneumococcal keratitis, topical 1% prednisolone phosphate, 0." | 1.28 | Topical anti-inflammatory agents in an animal model of microbial keratitis. ( Gritz, DC; Kwitko, S; Lee, TY; McDonnell, PJ, 1990) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (41.67) | 18.7374 |
1990's | 2 (16.67) | 18.2507 |
2000's | 2 (16.67) | 29.6817 |
2010's | 3 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hafiji, J | 1 |
Bhogal, B | 1 |
Rytina, E | 1 |
Burrows, NP | 1 |
McClintic, SM | 1 |
Srinivasan, M | 2 |
Mascarenhas, J | 1 |
Greninger, DA | 1 |
Acharya, NR | 2 |
Lietman, TM | 2 |
Keenan, JD | 1 |
Ray, KJ | 1 |
Prajna, L | 1 |
Geetha, M | 1 |
Karpagam, R | 1 |
Glidden, D | 1 |
Oldenburg, CE | 1 |
Sun, CQ | 1 |
McLeod, SD | 1 |
SCHEIBNER, M | 1 |
MITCHELL, JH | 1 |
Kapetanovic, MC | 1 |
Saxne, T | 1 |
Sjöholm, A | 1 |
Truedsson, L | 1 |
Jönsson, G | 1 |
Geborek, P | 1 |
Nagayama, Y | 1 |
Iwasaki, S | 1 |
Yamaguchi, H | 1 |
Yoshimura, A | 1 |
Isenberg, DA | 1 |
Lipkin, DP | 1 |
Mowbray, JF | 1 |
Fisher, C | 1 |
Davies, R | 1 |
Wilcox, LD | 1 |
De Rose, G | 1 |
Cooke, D | 1 |
Bates, AK | 1 |
Kirkness, CM | 1 |
Ficker, LA | 1 |
Steele, AD | 1 |
Rice, NS | 1 |
Gritz, DC | 1 |
Lee, TY | 1 |
Kwitko, S | 1 |
McDonnell, PJ | 1 |
Kishimoto, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Steroids for Corneal Ulcers Trial[NCT00324168] | Phase 4 | 500 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response.[NCT03762824] | Phase 4 | 300 participants (Actual) | Interventional | 2016-06-14 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
LogMAR (logarithm of the Minimum Angle of Resolution) is a measure of visual acuity in which the smaller values indicate better visual acuity. (NCT00324168)
Timeframe: 3 months from enrollment
Intervention | logMAR (Mean) |
---|---|
Steroid | 0.42 |
Placebo | 0.41 |
LogMAR (logarithm of the Minimum Angle of Resolution) is a measure of visual acuity in which the smaller values indicate better visual acuity. (NCT00324168)
Timeframe: 12 months from enrollment
Intervention | logMAR (Mean) |
---|---|
Steroid | 2.90 |
Placebo | 2.87 |
LogMAR (logarithm of the Minimum Angle of Resolution) is a measure of visual acuity in which the smaller values indicate better visual acuity. (NCT00324168)
Timeframe: 3 months from enrollment
Intervention | logMAR (Mean) |
---|---|
Steroid | 0.48 |
Placebo | 0.49 |
Best spectacle-corrected visual acuity (BSCVA) for this outcome is measured in logMAR (logarithm of the Minimum Angle of Resolution) in which smaller values indicate better visual acuity. Minimum inhibitory concentration (MIC) to moxifloxacin was measured by E test and a log2-transformation of MIC was used in all analyses. In this analysis we add MIC to the model examining BSCVA at 3 months. (NCT00324168)
Timeframe: 3 months after enrollment
Intervention | logMAR (Mean) |
---|---|
Steroid | 0.50 |
Placebo | 0.46 |
(NCT00324168)
Timeframe: 3 months from enrollment
Intervention | mm (Mean) |
---|---|
Steroid | 3.07 |
Placebo | 3.02 |
(NCT00324168)
Timeframe: At the time of perforation
Intervention | participants (Number) |
---|---|
Steroid | 7 |
Placebo | 8 |
This outcome measured time from enrollment to resolution of the epithelial defect in days for up to 21 days. For three weeks patients were examined every 3 days for size of epithelial defect until the defect was gone. (NCT00324168)
Timeframe: From enrollment up to 21 days
Intervention | days (Mean) |
---|---|
Steroid | 9.77 |
Placebo | 9.43 |
BSCVA measured in logMAR will be examined by categories infiltrate depth (categorized by depth percentage) by mean and standard deviation as well as in a regression model. (NCT00324168)
Timeframe: 3 months from enrollment
Intervention | logMAR (Mean) | ||
---|---|---|---|
>0-33% | >33%-67% | >67%-100% | |
Placebo | 0.26 | 0.47 | 0.86 |
Steroid | 0.35 | 0.52 | 0.80 |
BSCVA measured in logMAR will be estimated by causative organism (either Nocardia spp, Streptococcus pneumoniae, Moraxella spp, or Pseudomonas aeruginosa). BSCVA will be examined for each causative organism by mean and standard deviation as well as in a regression model. (NCT00324168)
Timeframe: 3 months after enrollment
Intervention | logMAR (Mean) | |||
---|---|---|---|---|
Nocardia spp | Streptococcus pneumoniae | Moraxella spp | Pseudomonas aeruginosa | |
Placebo | 0.36 | 0.52 | 0.26 | 0.45 |
Steroid | 0.54 | 0.49 | 0.46 | 0.53 |
Best spectacle-corrected visual acuity (BSCVA) for this subgroup analysis was measured in logMAR and then categorized by equivalent Snellen fractions (NCT00324168)
Timeframe: 3 months from enrollment
Intervention | logMAR (Mean) | ||
---|---|---|---|
<20/40 | 20/40 to 20/800 | Counting fingers (CF) or worse | |
Placebo | -0.02 | 0.38 | 1.15 |
Steroid | 0.06 | 0.36 | 1.00 |
Best-spectacle visual acuity (BSCVA) at 3 months from enrollment is stratified by categories of infiltrate/scar size and examined by treatment arm (NCT00324168)
Timeframe: 3 months from enrollment
Intervention | logMAR (Mean) | |||
---|---|---|---|---|
0-1.90 mm | 1.91-2.70 mm | 2.71-4.06 mm | 4.07-8.90 mm | |
Placebo | 0.19 | 0.29 | 0.53 | 0.96 |
Steroid | 0.18 | 0.39 | 0.53 | 0.85 |
1 trial available for prednisolone and Pneumococcal Infections
Article | Year |
---|---|
Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Bacteria; Corneal Ulcer; Double-Blind Method; Drug Resi | 2013 |
11 other studies available for prednisolone and Pneumococcal Infections
Article | Year |
---|---|
Bullous pemphigoid in infancy developing after the first vaccination.
Topics: Diphtheria; Glucocorticoids; Haemophilus Infections; Heptavalent Pneumococcal Conjugate Vaccine; Hum | 2010 |
Improvement in corneal scarring following bacterial keratitis.
Topics: Adult; Aged; Aza Compounds; Cicatrix; Corneal Ulcer; Eye Infections, Bacterial; Female; Fluoroquinol | 2013 |
[Intralumbar Solu-Dacortin treatment of severe pneumococcal meningitis].
Topics: Humans; Meningitis; Meningitis, Meningococcal; Meningitis, Pneumococcal; Pneumococcal Infections; Pr | 1961 |
PNEUMOCOCCAL MENINGO-ENCEPHALITIS. AN UNUSUAL CASE.
Topics: Ataxia; Body Image; Chloramphenicol; Encephalitis; Humans; Meningitis; Meningitis, Pneumococcal; Men | 1964 |
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibo | 2006 |
[Infective endocarditis successfully treated by early medical therapy in a patient with Henoch-Schönlein purpura nephritis under oral steroid therapy].
Topics: Adult; Endocarditis, Bacterial; Humans; IgA Vasculitis; Male; Nephritis; Penicillin G; Pneumococcal | 2007 |
Fatal pneumococcal epiglottitis in lupus overlap syndrome.
Topics: Adult; Epiglottitis; Female; Humans; Laryngitis; Lupus Erythematosus, Systemic; Myositis; Pneumococc | 1984 |
Use of the dog spleen for studying effects of irradiation and chemotherapeutic agents, with suggested uses of other organs.
Topics: Animals; Antineoplastic Agents; Azathioprine; Cyclophosphamide; Dogs; Fluorouracil; Leukocytes; Mech | 1976 |
Microbial keratitis after penetrating keratoplasty.
Topics: Adult; Aged; Aged, 80 and over; Chloramphenicol; Female; Graft Rejection; Humans; Keratitis; Keratit | 1990 |
Topical anti-inflammatory agents in an animal model of microbial keratitis.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Flurbiprofen; Ke | 1990 |
[Study on carbohydrate and insulin metabolism in experimental pneumococcal infections].
Topics: Animals; Blood Protein Electrophoresis; Blood Proteins; Carbohydrate Metabolism; Diabetes Mellitus, | 1965 |